Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Cell Line Models
100%
Receptor Knockout
100%
Multikinase
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
100%
Cetuximab
36%
UM-SCC
36%
Knockout Cell Lines
18%
Molecular Analysis
9%
Tumor
9%
Insulin-like Growth Factor 1 Receptor (IGF1R)
9%
Monotherapy
9%
Cell Proliferation
9%
Molecular Mechanism
9%
Treatment Response
9%
Functional Analysis
9%
Knock-in Mouse Model
9%
Transcriptome
9%
IGF1R Inhibitor
9%
Kinase Inhibitor
9%
Zinc Finger E-box Binding Homeobox 1 (ZEB1)
9%
Fibroblast Growth Factor Receptor 1 (FGFR1)
9%
Cell Viability Assay
9%
Poor Survival
9%
CRISPR-Cas9 System
9%
Receptor Targets
9%
Targeting Antibodies
9%
Complex Networks
9%
Survival Rate
9%
RNA Sequencing (RNA-seq)
9%
Receptor Activity
9%
Dual Inhibition
9%
Mesenchymal Phenotype
9%
Inhibitor Resistance
9%
Synergistic Activity
9%
FGFR Inhibitor
9%
If Inhibitor
9%
Resazurin
9%
EMT Genes
9%
EMT Phenotype
9%
Driving Resistance
9%
Debilitating Disease
9%
Immunology and Microbiology
Cell Line
100%
Neck
100%
Squamous Cell
100%
Epidermal Growth Factor
100%
Kinase
100%
Phosphotransferase
100%
Cetuximab
36%
XIAP
18%
Wild Type
18%
Transcriptome
9%
CRISPR/Cas9
9%
Cell Proliferation
9%
Upregulation
9%
Cell Viability
9%
Survival Rate
9%
Knockout Model
9%
Fibroblast Growth Factor Receptor 1
9%
Medicine and Dentistry
Phosphotransferase
100%
Head and Neck Squamous Cell Carcinoma
100%
Epidermal Growth Factor Receptor
100%
Cell Line
100%
Cetuximab
44%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Epithelial Mesenchymal Transition
22%
Monotherapy
11%
Clustered Regularly Interspaced Short Palindromic Repeat
11%
Cas9
11%
Phosphotransferase Inhibitor
11%
Cell Proliferation
11%
Treatment Response
11%
Upregulation
11%
Kinase
11%
Survival Rate
11%
Cell Viability Assay
11%
Knockout Model
11%
Tumor
11%
Transcriptome
11%
Fibroblast Growth Factor Receptor 1
11%
Diseases
11%
Resazurin
11%
Biochemistry, Genetics and Molecular Biology
Phosphotransferase
100%
Kinase
100%
Epidermal Growth Factor Receptor
100%
Cetuximab
36%
Wild Type
18%
XIAP
18%
Growth Factor Receptor Inhibitor
18%
EMT
18%
CRISPR/Cas9
9%
Knockout Model
9%
Upregulation
9%
Cell Proliferation
9%
Cell Viability
9%
Survival Rate
9%
ZEB1
9%
Fibroblast Growth Factor Receptor 1
9%
Transcriptome
9%
Molecular Mechanism
9%
Neuroscience
Kinase
100%
Cell Line
100%
Epidermal Growth Factor Receptor
100%
Cetuximab
36%
Growth Factor Receptor Inhibitor
18%
XIAP
18%
Transcriptome
9%
ZEB1
9%
CRISPR
9%
Cell Proliferation
9%
Cell Viability
9%
Fibroblast Growth Factor Receptor 1
9%